Gathering the record
Relay is organizing the evidence and source boundaries.
Endogenous thiol tripeptide / cellular redox buffer
Glutathione is a small molecule your body makes to help control redox balance and process peroxides and reactive chemicals. People research it for antioxidant support, skin pigmentation, liver health, recovery, breathing conditions, and general wellness. Oral glutathione can raise measured glutathione, but stronger clinical benefits are inconsistent, route-specific, or not demonstrated. Injectable products add sterility and endotoxin risks.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Glutathione is a small molecule made by the body that helps cells manage chemical stress. It is not a receptor-targeted peptide drug, even though it is built from three amino acids.
Researchers ask whether changing glutathione levels can improve outcomes in settings involving oxidative stress, skin pigmentation, lung disease, neurologic disease, or nutritional status. Route and formulation matter because measured exposure differs.
Controlled oral research shows that glutathione can raise measured glutathione in healthy adults. That target engagement has not reliably translated into clinical benefit: larger inhaled and disease-specific trials were neutral, and a small intravenous Parkinson study did not show a significant efficacy difference.
Which people, routes, and formulations might gain a durable clinical benefit remains uncertain. Intravenous efficacy evidence is especially limited, and compounded injections introduce product-quality, sterility, and endotoxin questions that oral studies cannot answer.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A randomized controlled study investigated whether oral reduced glutathione changed measured glutathione stores in healthy, non-smoking adults.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Controlled oral, inhaled, intravenous, and topical studies examine biomarkers and disease-specific outcomes using very different formulations.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Oral target engagement is reproducible, but meaningful clinical effects are inconsistent, route-specific, and often unsupported by larger trials.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The endpoints were glutathione biomarkers, not symptoms, disease outcomes, recovery, cognition, or longevity. The oral study cannot establish the effects or safety of inhaled, topical, or intravenous formulations. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Controlled oral trials show that direct glutathione can raise glutathione biomarkers; larger condition-specific trials show that target delivery does not necessarily improve clinical outcomes
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Which formulation- and route-specific biomarker changes, if any, translate into meaningful durable health outcomes and what long-term safety looks like
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
Cells make glutathione from glutamate, cysteine, and glycine. Reduced glutathione (GSH) helps handle peroxides and electrophiles and can be oxidized to GSSG.
Those interventions may affect glutathione synthesis, but they are different molecules with different studies, exposures, and safety profiles.
A six-month controlled trial increased glutathione in several tissues, and a 2026 crossover pilot showed that formulation affected short-term blood exposure.
The 14-person 2026 pilot found higher blood exposure with one branded micellar product than a standard product at the tested doses.
Sputum measurements confirmed delivery, yet lung function, exacerbations, quality of life, and oxidative or inflammatory markers were not meaningfully improved.
The 24-week GROW study found no significant difference in growth, BMI, or measured inflammation compared with placebo.
A 21-person randomized pilot found no statistically significant difference in Parkinson rating-scale changes.
A 2025 systematic review found some melanin-index improvement in small oral and topical studies, but study quality was mixed and the single IV study was not convincingly positive.
FDA investigated acute reactions after IV glutathione and found excessive bacterial endotoxin in the bulk ingredient used to compound the injections.
There is no approved U.S. glutathione label that establishes a standard therapeutic indication, injectable formulation, route, dose, reconstitution method, or storage procedure.
Oral, inhaled, topical, and IV studies used different formulations for different research questions. Those protocols describe experiments; they are not interchangeable instructions.
These are common reasons people discuss glutathione, but the direct evidence reviewed here is biomarker-focused, mixed, condition-specific, or negative.
Mechanisms
Reduced glutathione (GSH) is a γ-glutamyl-cysteinyl-glycine tripeptide that participates in the GSH/GSSG redox couple, serves as an electron donor for glutathione peroxidases, and is conjugated to electrophiles by glutathione S-transferases. Human evidence establishes that direct oral supplementation can alter blood and tissue glutathione biomarkers and that oral formulation affects pharmacokinetics. Those findings do not establish broad clinical benefit. A 153-person inhaled cystic-fibrosis trial confirmed airway delivery without clinically relevant improvement, a later oral pediatric cystic-fibrosis trial was negative, and a 21-person IV Parkinson pilot did not find a significant efficacy difference. Skin-pigmentation studies show mixed modest signals with substantial route and study-quality limitations. FDA has documented endotoxin-related reactions involving compounded IV glutathione.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized, double-blind crossover pharmacokinetic pilot followed by a 30-day single-arm tolerability phase
14 healthy adults
The branded micellar formulation produced higher baseline-adjusted glutathione exposure and peak response than the standard preparation at the administered doses. Thirty-day clinical safety markers did not change significantly.
Study administration: Micellar glutathione 300 mg, liposomal glutathione 300 mg, and standard glutathione 500 mg in the crossover phase; micellar glutathione 600 mg/day in the follow-up
Limitations: Only 14 healthy adults participated, the follow-up was uncontrolled and short, branded formulations were studied, and the endpoints were pharmacokinetic and laboratory measures rather than clinical benefit.
Prospective, multicenter, randomized, double-blind, placebo-controlled oral trial
Young children with cystic fibrosis and pancreatic insufficiency; 58 completed the trial
Oral glutathione did not significantly improve growth, BMI, inflammatory markers, or the other secondary outcomes compared with placebo. It was generally well tolerated.
Study administration: Daily oral reduced glutathione or placebo in a disease-specific pediatric study
Limitations: This pediatric cystic-fibrosis trial does not answer general-wellness questions, but it shows that oral exposure and plausible antioxidant biology do not guarantee clinical benefit.
Randomized, double-blind, placebo-controlled parallel-group biomarker trial
54 healthy, non-smoking adults
Both oral glutathione groups increased measured glutathione in several body compartments. Larger and longer exposure generally produced larger changes, and levels returned toward baseline after washout.
Study administration: Oral reduced glutathione 250 mg/day, 1,000 mg/day, or placebo; these were study exposures, not general dosing guidance
Limitations: The trial established biomarker target engagement in healthy adults, not improvement in fatigue, liver disease, exercise recovery, cognition, longevity, skin outcomes, or another clinical condition.
Multicenter, randomized, double-blind, placebo-controlled inhalation trial
153 people with cystic fibrosis aged 8 years or older and baseline FEV1 of 40% to 90% predicted
Glutathione reached the airways, but it did not produce clinically relevant improvement in lung function, exacerbations, quality of life, or measured oxidative and inflammatory outcomes. Adverse-event incidence was similar to placebo.
Study administration: 646 mg inhaled glutathione in 4 mL or placebo every 12 hours through an investigational nebulizer
Limitations: The result applies to one inhaled regimen in cystic fibrosis. It does not answer oral, topical, or IV questions, and confirmed delivery does not prove clinical benefit.
Randomized, double-blind, placebo-controlled intravenous pilot
21 people with Parkinson's disease whose motor symptoms were not adequately controlled; 20 contributed post-randomization efficacy data
The pilot was tolerated, but differences in Parkinson rating-scale changes were not statistically significant during treatment or follow-up.
Study administration: 1,400 mg intravenous glutathione or placebo three times weekly; this was a disease-specific research protocol
Limitations: The sample was very small and designed for preliminary safety and signal detection. It cannot establish Parkinson efficacy, an optimal IV protocol, or benefit for healthy people.
Systematic review of oral, topical, and intravenous glutathione studies for skin lightening and melasma
Five randomized oral trials, one open oral study, topical studies, and one placebo-controlled intravenous study
Small oral and topical studies reported some melanin-index improvement, but effects were variable, not durable, and supported by a mixed-quality evidence base. The single IV study was not convincingly positive.
Study administration: Oral, topical, and intravenous glutathione across heterogeneous formulations and study designs
Limitations: Routes, products, populations, and outcome methods differed, and nearly as many studies had high as low risk of bias. The review does not establish injectable skin-lightening efficacy or safety.
Safety snapshot
Compounded injectable glutathione has a documented endotoxin and sterile-product risk.
Other human evidenceThis was a product-quality event. It should not be converted into an intrinsic side-effect rate for all glutathione products.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Compounded injectable glutathione has a documented endotoxin and sterile-product risk.
Other human evidenceThis was a product-quality event. It should not be converted into an intrinsic side-effect rate for all glutathione products.
Open sourceThe current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-03-01 · PMID 41897500 · NCT06345950 · DOI 10.3390/antiox15030354
2025-06-01 · PMID 39444151 · DOI 10.1111/ijd.17535
2020-12-01 · PMID 32960827 · NCT03020719 · DOI 10.1097/MPG.0000000000002948
2019-06-07
2015-03-01 · PMID 24791752 · NCT01044277 · DOI 10.1007/s00394-014-0706-z
2013-07-01 · PMID 23631796 · NCT00506688 · DOI 10.1164/rccm.201303-0427OC
2009-05-15 · PMID 19230029 · DOI 10.1002/mds.22401